​

CRISPR Therapeutics Ownership | Who Owns CRISPR Therapeutics?

OverviewForecastRevenueFinancialsChart

CRISPR Therapeutics Ownership Summary

CRISPR Therapeutics is owned by 53.48% institutional investors, 5.90% insiders, and 40.62% retail investors. Ark investment management is the largest institutional shareholder, holding 9.85% of CRSP shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 5.92% of its assets in CRISPR Therapeutics shares.

CRSP Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockCRISPR Therapeutics53.48%5.90%40.62%
SectorHealthcare Stocks 35.56%12.08%52.36%
IndustryBiotech Stocks 35.43%12.01%52.56%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ark investment management9.46M9.85%$516.00M
Blackrock funding, inc. /de8.35M8.69%$455.35M
Orbis allan gray5.45M5.67%$297.20M
Capital world investors4.75M4.94%$259.04M
State street4.32M4.50%$235.70M
Blackrock2.78M3.40%$150.03M
Gsk3.22M3.35%$175.65M
Geode capital management2.51M2.61%$136.92M
Vanguard group2.27M2.48%$118.95M
T. rowe price investment management2.05M2.14%$111.97M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Gsk3.22M29.17%$175.65M
Sr one capital management, lp2.04M10.70%$111.19M
Spear rsc165.00K6.29%$8.91M
Versant venture management148.83K4.99%$8.12M
Ecor1 capital1.39M3.68%$75.77M
Nea management company1.06M3.64%$57.73M
Ark investment management9.46M3.35%$516.00M
Contrarius investment management685.72K2.32%$37.04M
Green alpha advisors55.80K2.04%$3.04M
Eagle health investments lp197.00K1.87%$10.64M

Top Buyers

HolderShares% AssetsChange
Sixth street partners management company1.06M0.01%1.06M
D. e. shaw893.81K0.02%893.81K
Blackrock funding, inc. /de8.35M0.01%668.90K
Two sigma investments, lp1.99M0.08%505.57K
State street4.32M0.01%339.17K

Top Sellers

HolderShares% AssetsChange
Ark investment management9.46M3.35%-1.85M
Loomis sayles & co l p---968.13K
T. rowe price investment management2.05M0.07%-899.58K
Two sigma advisers, lp572.97K0.07%-771.73K
Orbis allan gray5.45M1.02%-656.85K

New Positions

HolderShares% AssetsChangeValue
Sixth street partners management company1.06M0.01%1.06M$57.69M
D. e. shaw893.81K0.02%893.81K$48.75M
Logos global management lp300.00K0.70%300.00K$16.36M
Norges bank270.76K0.00%270.76K$14.77M
Campbell & co investment adviser107.53K0.31%107.53K$5.86M

Sold Out

HolderChange
Carolina wealth advisors-1.00
Tortoise investment management-1.00
Impact partnership wealth-1.00
Frazier financial advisors-2.00
Transce3nd-2.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026387-25.00%48,093,713-37.13%530.74%183-27.09%90-31.82%
Dec 31, 2025430-10.60%67,314,484-6.81%731.07%208-7.96%108-11.48%
Sep 30, 2025461-2.12%71,905,056-0.80%821.19%220-6.78%11715.84%
Jun 30, 20254579.33%72,312,35012.69%831.49%22831.03%101-2.88%
Mar 31, 202516-96.30%3,317,986-94.86%30.07%8-95.58%3-97.52%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Disruptive Innovation Full Composite5.83M5.92%-1.50M
ARK Innovation ETF5.54M5.73%53.03K
iShares Russell 2000 ETF2.35M2.43%-41.76K
ARK Genomic Revolution ETF2.08M2.15%45.49K
ARK Genomic Revolution2.05M2.08%57.78K
State Street® SPDR® S&P® Biotech ETF1.98M2.05%4.54K
Capital Group New Perspective Comp1.94M1.97%-
American Funds New Perspective A1.94M1.97%-
American Funds SMALLCAP World A1.69M1.72%46.44K
SPDR® S&P Biotech ETF1.40M1.53%3.11K

Recent Insider Transactions

DateNameRoleActivityValue
May 29, 2026Patel Naimish Chief Medical OfficerSell$210.58K
Mar 23, 2026KASINGER JAMES R. General Counsel and SecretarySell$148.85K
Mar 23, 2026Kulkarni Samarth Chief Executive OfficerSell$468.74K
Mar 23, 2026Prasad Raju Chief Financial OfficerSell$173.46K
Mar 16, 2026Patel Naimish Chief Medical OfficerSell$152.02K

Insider Transactions Trends

DateBuySell
2026 Q1-19
2025 Q4-6
2025 Q341
2025 Q2-1
2025 Q1117

CRSP Ownership FAQ

Who Owns CRISPR Therapeutics?

CRISPR Therapeutics shareholders are primarily institutional investors at 53.48%, followed by 5.90% insiders and 40.62% retail investors. The average institutional ownership in CRISPR Therapeutics's industry, Biotech Stocks , is 35.43%, which CRISPR Therapeutics exceeds.

Who owns the most shares of CRISPR Therapeutics?

CRISPR Therapeutics’s largest shareholders are Ark investment management (9.46M shares, 9.85%), Blackrock funding, inc. /de (8.35M shares, 8.69%), and Orbis allan gray (5.45M shares, 5.67%). Together, they hold 24.22% of CRISPR Therapeutics’s total shares outstanding.

Does Blackrock own CRISPR Therapeutics?

Yes, BlackRock owns 3.40% of CRISPR Therapeutics, totaling 2.78M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 150.03M$. In the last quarter, BlackRock increased its holdings by 231.42K shares, a 9.09% change.

Who is CRISPR Therapeutics’s biggest shareholder by percentage of total assets invested?

Gsk is CRISPR Therapeutics’s biggest shareholder by percentage of total assets invested, with 29.17% of its assets in 3.22M CRISPR Therapeutics shares, valued at 175.65M$.

Who is the top mutual fund holder of CRISPR Therapeutics shares?

ARK Disruptive Innovation Full Composite is the top mutual fund holder of CRISPR Therapeutics shares, with 5.92% of its total shares outstanding invested in 5.83M CRISPR Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools